Xconomy

MAY 30, 2018

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) named four new board members Tuesday, after the four directors who fired founding CEO Joseph Payne resigned as part of a settlement agreement that was approved Monday by an Israeli court. No financial terms were disclosed.

Arcturus 56

Arcturus San Diego Develop Development 56

Xconomy

FEBRUARY 2, 2018

Arcturus Therapeutics (NASDAQ: ARCT ) said today it has fired co-founder and CEO Joseph E. Payne (on the right in above photo), and named Mark Herber, vice president of business development and alliance management, as interim president. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 56

Arcturus San Diego Pricing Report 56

Xconomy

MAY 30, 2017

San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.

Arcturus 65

Arcturus San Diego Research Funding 65

Xconomy

FEBRUARY 27, 2018

The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing. The San Diego drug developer said late Monday that the typically routine step of ratifying the company’s auditor failed a shareholder vote.

Arcturus 49

Arcturus San Diego Report Develop 49

Xconomy

MAY 31, 2018

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) on Thursday reinstated fired CEO Joseph Payne and named ResMed (NYSE: RMD ) founder Peter Farrell as chairman of the company’s new board of directors. He co-founded Arcturus and is the company’s largest shareholder, with a 13.7 percent stake.

Arcturus 49

Arcturus San Diego Develop Development 49

Xconomy

MARCH 29, 2018

The board that fired Arcturus Therapeutics co-founder and CEO Joseph E. Payne earlier this year unleashed a new broadside this week in the ongoing battle for control of the San Diego-based RNA drug developer. Payne, who. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 49

Arcturus San Diego Develop Development 49

socalTECH

FEBRUARY 25, 2009

San Diego-based XIFIN , a publisher of hosted revenue cycle management software for diagnostic laboratories, reported Tuesday that it has added two members to its executive staff. Most recently, XIFIN said, Zaniboni was CFO of AviaraDx, while Taylor served as vice president of marketing and corporate development for Acclerys Inc.

Arcturus 100

Arcturus Marketing IBM IBM 100

Xconomy

MAY 3, 2018

In the five years since it was founded, San Diego-based Arcturus Therapeutics (NASDAQ: ARCT ) says it has built a versatile platform for developing a variety of RNA-based medicines. Dueling lawsuits between the ousted CEO and the board could consume. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 49

Arcturus Develop Development San Diego 49

Xconomy

APRIL 17, 2020

Alnylam had sold the drug’s development and commercialization rights seven years ago. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol. Now in the hands of Novartis (NYSE: NVS ), the potential blockbuster seller awaits an FDA decision.

Equity 84

Equity Activity Marketing Company 84

Xconomy

JANUARY 3, 2019

As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat these “superbugs.” San Diego’s Forge Therapeutics is among those targeting gram-negative bacteria, a type of bacteria that has a protective outer membrane that makes it especially resistant to drugs.

Develop 65

Develop Development San Diego Arcturus 65

Xconomy

FEBRUARY 9, 2018

A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. But the results, touted as positive, left more questions than answers.

Help 58

Help Develop Development Arcturus 58